Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » Channel 7 reports on life changing access to Belzutifan for VHL Patients

Channel 7 reports on life changing access to Belzutifan for VHL Patients

  • January 29, 2025

Advocacy is at the heart of what NeuroEndocrine Cancer Australia (NECA) does, and stories like this showcase the powerful work happening behind the scenes to support patients across Australia.

NeuroEndocrine Cancer Australia (NECA), alongside Von Hippel-Lindau (VHL) patients Amelia and Greta, expresses immense gratitude to Channel 7 for shining a spotlight on VHL and the life-changing access to Belzutifan, the only treatment available for tumours associated with this condition.

On Tuesday, 28th January, Natarsha Belling’s interview with Amelia and Greta aired nationally during the midday news segment, followed by a comprehensive online article that delved deeper into their journey and that of others diagnosed with VHL. This dual coverage has helped raise crucial awareness about VHL and the transformative impact of Belzutifan.

NECA extends heartfelt thanks to Amelia and Greta for their patience and collaboration with NECA and Channel 7 in bringing this story to life. Their courage and willingness to share their experiences have amplified the voices of many VHL patients nationwide, reflecting NECA’s commitment to advocacy and its ongoing efforts to ensure all patients have equitable access to vital treatments and support.

Read the online article here

Share this post

Recent posts

ACCN Innovations Showcase 2025

July 8, 2025

Radio National Interview: Changing Australia June 2025

June 30, 2025

Adelaide NET Patient Forum 2025

June 24, 2025

CNSA & ICCN 2025 Congress: Global Voices, Local Actions

June 24, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousFunding announced for a dedicated Neuroendocrine Cancer McGrath Nurse in WA
NextMedia Coverage Highlights VHL Awareness and Equity in Cancer CareNext

Related Posts

ACCN Innovations Showcase 2025

The annual Australian Comprehensive Cancer Network (ACCN) Innovations Showcase was held at Peter MacCallum Cancer Centre in Melbourne this year. There were several hundred who

Radio National Interview: Changing Australia June 2025

Rare cancers can be extremely difficult to diagnose, and it can take years of misdiagnoses before a culprit is found and patients get adequate treatment.

Adelaide NET Patient Forum 2025

Pictured – DR Ria Joseph, Dr Chad Han, A/Prof Gabby Cehic, Meredith Cummins, Dr Rebekah Chew, Jessica Mercurio and Dr Rahul Solanki Thank you to

CNSA & ICCN 2025 Congress: Global Voices, Local Actions

NECA proudly attended the CNSA & ICCN 2025 Annual Congress, held at the Adelaide Convention Centre from 18–21 June 2025. This landmark event was a

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin